A Diagnostic Stewardship Intervention to Improve Utilization of 1,3 β-D-Glucan Testing at a Single Academic Center: Five-Year Experience
Open Forum Infectious Diseases · 28.06.2024 · 11 (7)
DOI: 10.1093/ofid/ofae358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 01.07.2024. Verfasst von Jordan D Colson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
(1,3)- β-D-glucan (BDG) testing is one of the noninvasive tests to aid diagnosis of invasive fungal infections (IFIs). The study results have been heterogenous, and diagnostic performance varies depending on the risks for IFI. Thus, it is important to select appropriate patients for BDG testing to prevent false-positive results. An algorithmic diagnostic stewardship intervention was instituted at a single academic medical center to improve BDG test utilization.
Methods
The BDG test order in the electronic health record was replaced with the BDG test request order, which required approval to process the actual test order. The approval criteria were (1) immunocompromised or intensive care unit patient and (2) on empiric antifungal therapy, or inability to undergo invasive diagnostic procedures. A retrospective observational study was conducted to evaluate the efficacy of the intervention by comparing the number of BDG tests performed between 1 year pre- and post-intervention. Safety was assessed by chart review of the patients for whom BDG test requests were deemed inappropriate and rejected.
Results
The number of BDG tests performed per year decreased by 85% from 156 in the pre-intervention period to 24 in the post-intervention period. The average monthly number of BDG tests performed was significantly lower between those periods (P = .002). There was no delay in IFI diagnosis or IFI-related deaths in the patients whose BDG test requests were rejected. The sustained effectiveness of the intervention was observed for 5 years.
Conclusions
Institution of the diagnostic stewardship intervention successfully and safely improved BDG test utilization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Internal Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA.
- Department of Infectious Diseases, Kameda Medical Center, Kamogawa, Chiba, Japan.
- Section of Infectious Diseases, Department of Internal Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA.
- Department of Pathology and Laboratory Medicine, Rutgers University Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
- Department of Pathology and Laboratory Medicine, Monmouth Medical Center, Long Branch, New Jersey, USA.
ORCID-Profile: Masako Mizusawa
Zitieren
APA
Colson, J. D., Kendall, J. A., Yamamoto, T., & Mizusawa, M. (2024). A Diagnostic Stewardship Intervention to Improve Utilization of 1,3 β-D-Glucan Testing at a Single Academic Center: Five-Year Experience. Open Forum Infectious Diseases, 11(7). https://doi.org/10.1093/ofid/ofae358
Vancouver
Colson JD, Kendall JA, Yamamoto T, Mizusawa M. A Diagnostic Stewardship Intervention to Improve Utilization of 1,3 β-D-Glucan Testing at a Single Academic Center: Five-Year Experience. Open Forum Infectious Diseases. 2024;11(7). doi:10.1093/ofid/ofae358
BibTeX
@article{Colson2024,
author = {Colson, Jordan D and Kendall, Jonathan A and Yamamoto, Takeru and Mizusawa, Masako},
title = {A Diagnostic Stewardship Intervention to Improve Utilization of 1,3 β-D-Glucan Testing at a Single Academic Center: Five-Year Experience},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {7},
doi = {10.1093/ofid/ofae358}
}
EUVIMED